lapatinib has been researched along with topotecan in 9 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (topotecan) | Trials (topotecan) | Recent Studies (post-2010) (topotecan) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 2,392 | 626 | 792 |
| Protein | Taxonomy | lapatinib (IC50) | topotecan (IC50) |
|---|---|---|---|
| Cytochrome P450 3A4 | Homo sapiens (human) | 1.5211 | |
| DNA topoisomerase 1 | Homo sapiens (human) | 0.8525 | |
| DNA topoisomerase 2-alpha | Homo sapiens (human) | 0.605 | |
| DNA topoisomerase 2-beta | Homo sapiens (human) | 0.605 | |
| Hypoxia-inducible factor 1-alpha | Homo sapiens (human) | 0.06 | |
| Multidrug and toxin extrusion protein 2 | Homo sapiens (human) | 8.6 | |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 1.3 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 0.17 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 7 (77.78) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Adjei, AA; Erlichman, C; Felten, SJ; Flatten, KS; Friedman, R; Gálvez-Peralta, M; Gilmer, TM; Jewell, RC; Kaufmann, SH; Koch, KM; Mandrekar, S; Molina, JR; Mullin, RJ; Reid, JM; Rubin, SD | 1 |
| Dakhilm, SR; Haluska, P; Hartmann, LC; Keeney, GL; Moore, DF; Oberg, AL; Peethambaram, PP; Rowland, KM; Weroha, SJ; Ziegler, KL | 1 |
| Campone, M; Eierman, W; Greil, R; Kaufman, B; Lane, SR; Lin, NU; Rubin, SD; Steplewski, K; Winer, EP; Zembryki, D | 1 |
| Blanc-Fournier, C; Bourgeois, H; Briand, M; Clarisse, B; Fabbro, M; Joly, F; Krieger, S; Leconte, A; Lheureux, S; Lortholary, A; Pautier, P; Petit, T; Plantade, A; Richard, N; Selle, F; Vilquin, P; Weber, B | 1 |
| Cao, KI; Kirova, YM | 1 |
| Chen, L; Chen, Z; Fu, L; Li, F; Wang, F; Wang, X; Zhang, W | 1 |
| Li, H; Sui, S; Wang, L; Xu, S; Zhang, L; Zhang, X; Zheng, X | 1 |
2 review(s) available for lapatinib and topotecan
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Radiotherapy plus concomitant systemic therapies for patients with brain metastases from breast cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Dacarbazine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Adjuvant; Receptor, ErbB-2; Temozolomide; Thalidomide; Topoisomerase I Inhibitors; Topotecan; Trastuzumab; Vinblastine; Vinorelbine | 2014 |
4 trial(s) available for lapatinib and topotecan
| Article | Year |
|---|---|
Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Female; Humans; In Vitro Techniques; Lapatinib; Male; Maximum Tolerated Dose; Mice; Middle Aged; Neoplasms; Quinazolines; Topotecan; Xenograft Model Antitumor Assays | 2008 |
Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lapatinib; Middle Aged; Neoplasm Proteins; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Quinazolines; Receptor, ErbB-2; Survival Rate; Topotecan | 2011 |
Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Topotecan | 2011 |
Expected benefits of topotecan combined with lapatinib in recurrent ovarian cancer according to biological profile: a phase 2 trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Drug Administration Schedule; Female; Humans; Lapatinib; Metabolome; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Quinazolines; Recurrence; Risk Assessment; Topotecan; Treatment Outcome; Young Adult | 2012 |
3 other study(ies) available for lapatinib and topotecan
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
ABCG2-overexpressing H460/MX20 cell xenografts in athymic nude mice maintained original biochemical and cytological characteristics.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Disease Models, Animal; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Heterografts; Lapatinib; Mice, Nude; Mitoxantrone; Neoplasm Proteins; Neoplasm Transplantation; Quinazolines; Topotecan | 2017 |
Inhibition of tumor propellant glutathione peroxidase 4 induces ferroptosis in cancer cells and enhances anticancer effect of cisplatin.
Topics: A549 Cells; Animals; Carbamates; Cell Movement; Cisplatin; Dipeptides; DNA Methylation; Epigenesis, Genetic; Ferroptosis; Heterografts; Histones; Humans; Lapatinib; Mice; Neoplasm Invasiveness; Neoplasms; Phospholipid Hydroperoxide Glutathione Peroxidase; Piperazines; Pyridines; Topotecan | 2020 |